Fragment 176 191

ragment 176-191 also popular referred to as HGH frag 176-191 is a modified version of the amino acids from number 176 to 191 polypeptide. The isolation of these amino acids can be credited to researchers from Monash University, the scientist discovered the main active point of the polypeptide is between the amino acid 176-191, this fragment had the ability to induce lipolysis. The region is less than ten percent of the GH size, moreover the fragment has no effect on insulin resistance or growth. The mechanism of action of the hormone is biomimicry, it mimics the functionality of growth hormone, which is known to regulate fat metabolism, just like GH fragment 176-191 inhibits lipogenesis and promotes lipolysis .

Research indicates that when the supply of vital nutrients to the adipocytes is inhibited the adipocytes denature and thereafter excreted this constantly leads to loss of mass from the peripheral organs. Within a short period, fragment 176-191 increases serum glucose and plasma insulin, moreover it acts in synergy with fragments 172-191, 178-191, and 177-191. Research shows that the functionality of the polypeptide largely depends on the informational sequence and the peptide should be presented in the right conformation and configuration. The region where the fragment has a high affinity to different kinds of proteases and it is rich in amino acids such as proline. The change in the conformation of the peptide results in cytoplasmic domain band 3 on the erythrocyte membrane protein, which works as a pivot to the two supporting domains.

Moreover recent studies shows that fragment 176-191 has lipolytic activity without a significant influence on the serum glucose,  and it does not induce hyperglycemia. In addition, fragment 176-191 does not compete for the HGH receptors and this indicates that it can prevent lypodystrophy. The synergistic action when combined with GHRP and GHRH makes the fragment one of the best peptides in inducing the release of growth hormone from the anterior lobe of pituitary gland. Moreover, fragment 176-191 has no effect on the glucose levels and the functionality of thyroxine as per research. Studies shows that Fragment 176-191 is has a better half life than GHRH and other hexapeptide therefore the efficacy and effectiveness is enhanced than the other secretagogues since the active component of the entire GH chain is mainly located in the 176-191 region of the amino acid chain.